Women's Input on Sexual Health (WISH)
|ClinicalTrials.gov Identifier: NCT02057419|
Recruitment Status : Active, not recruiting
First Posted : February 7, 2014
Last Update Posted : December 30, 2016
|Condition or disease||Phase|
|Sexual and Reproductive Health||Phase 4|
Background: Sexual and reproductive health (SRH) is a global public health priority. Providing efficacious SRH technologies that have the greatest likelihood of use will have the greatest impact on women's health. Critical to use is "acceptability." However, current conceptualizations of adherence and acceptability fail to fully articulate and account for patterns of use and non-use. This research hypothesizes that a new model of use, Effective Use, is required. If correct, and if developers utilize an Effective Use model, a shift from the current "acceptability = adherence" paradigm would offer new insights in the development of SRH technologies that will result in increased use and improved SRH outcomes. If the model can be fully realized, women will have the best reproductive health technologies science can provide. The impact on global public health would be far-reaching, affecting reproductive health in women and men: decreasing STI incidence, minimizing unplanned pregnancies, and decreasing morbidity and mortality due to a range of other reproductive health conditions.
Conditions: There will be 2 experimental conditions: sexual lubricant use and contraceptive use. [NOTE: The protocol has been revised. Protocol 1 is no longer recruiting - Protocol 1: Each participant will use 3 different SRH products for 3 months each. Recruitment for Protocol 2 is ongoing for the contraceptive use condition only. - Protocol 2: Each participant will use 1 product for 6 months, or 2 products, each for 3 months. This will be dependent on the user's choice.] The sexual lubricant use condition will include gel, film, and capsule. The contraceptive use condition will include gel, intravaginal ring, and oral contraceptive pill. The order in which participants experience each delivery method will be randomized.
Methodology and Data Collection: Volunteers (N~20-30) will first be screened for the study using a brief questionnaire. Those who are interested in contraception and are eligible based on their responses to the prescreen will then complete a clinical screening visit (contraceptive arm only) and pregnancy test. Those who are interested in lubricants and are eligible based on their responses to the prescreen, and those who are eligible after clinical screening (contraception arm), will complete a survey that asks questions about demographics and sexual and reproductive history.
During the course of the study, participants will evaluate three study products (contraceptives OR sexual lubricants). Each product will be used for three consecutive months. Participants will be randomly assigned to the order in which they will try the three products. They will be given (lubricants), or prescribed (contraceptives) a three month supply of the product at the beginning of each use period. Participants will be required to complete a brief phone survey (<5 minutes) every day, beginning the day after they start their first product evaluation period and continuing until they complete their final study visit (approximately 9 months). The phone survey includes a short set of questions about sexual behavior and product use during the time since the last phone survey (about 24 hours). About once a month, each participant will be required to complete a web survey about their experience with the study product.
Every three months, participants will meet with research staff and, if necessary, the study clinician. All participants will be tested for pregnancy, and will be given, or prescribed, the next study product. Participants will also complete an individual in-depth interview with study staff about their experiences in the study. Participants will repeat these steps for the final (third) study product. After a participant has tried all three products, she will meet with a clinician (contraceptive arm only) to follow up clinically about her contraception options post-study participation. All participants complete a final survey that will ask about their experiences with all three study products, and about what kinds of products, if any, they might be interested in using in the future. Participants will also complete a final in-depth interview.
|Study Type :||Observational|
|Actual Enrollment :||35 participants|
|Official Title:||K24: Advancing Reproductive Health: Women's Input on Sexual Health (Project WISH)|
|Study Start Date :||April 2014|
|Primary Completion Date :||August 2016|
|Estimated Study Completion Date :||March 2018|
Protocol 1: 3-month use period for each of 3 contraceptive methods, randomly ordered. intravaginal ring, oral contraceptive pill, spermicide+condom; dosage and frequency as instructed...
Protocol 2: 3-month use period for 1st randomly assigned contraceptive method. At end of use period, user chooses to continue on 1st method or to switch to 2nd randomly assigned method for remaining 3-month use-period.
Sexual Lubricant Method
3-month use period for each of 3 sexual lubricant methods, randomly ordered. gel formulation, film formulation, insert formulation; dosage and frequency as instructed
- Product Use [ Time Frame: up to an average of 8-9 months ]Product use will be assessed on a daily basis, whether products are daily use regimens or pericoital regimens. There are 3 3-month use periods; therefore, daily product use measures will be collected, on average, through 9-10 months of use.
- USPE Scale Scores [ Time Frame: up to an average of 8-9 months ]User sensory perceptions and experiences (USPEs) with study products will be captured approximately monthly over a 90 day use period for each product evaluated. There are 3 use periods, therefore, the final USPE results will occur approximately 8-9 months following enrollment
- Experience and Adherence Narratives [ Time Frame: average of 9-10 months ]Participants will complete an in-depth qualitative interview (IDI) about their experiences with the study products following each 3 month use period. There are 3 use periods, therefore, the final IDI will occur approximately 9-10 months from enrollment
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02057419
|United States, Rhode Island|
|The Miriam Hospital: Centers for Behavioral & Preventive Medicine|
|Providence, Rhode Island, United States, 02906|
|Principal Investigator:||Kate Guthrie, PhD||The Miriam Hospital: Centers for Behavioral & Preventive Medicine|